Healthcare
Pliant Therapeutics, Inc.(PLRX)
Live Price
Offline$1.16
-1.69% today
1Y Change
-7.20%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $70.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +30.0%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pliant Therapeutics, Inc. (PLRX) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $1.16 and down 7.2% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +30.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +30.0%, free cash flow +19.2% with operating margin 0.0% and ROIC -73.2%. Stock Foundry combines PLRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +30.0%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -1.3% | +5.6% | -3.0% |
2026 Mar 11, 2026 | +16.7% | +6.0% | -3.8% | +1.5% |
2025 Nov 6, 2025 | +18.9% | +4.6% | +12.4% | -20.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PLRX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PLRX Max Drawdown
-41.71%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PLRX and SPY.
Company Overview
Pliant Therapeutics, Inc.
NASDAQ Global Select
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avร6 and avร1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avร1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
- Leadership
- Bernard Coulie
- IPO Date
- Jun 3, 2020
- Employees
- 171
- Street Address
- 260 Littlefield Avenue
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 481 6770
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 0.4
Growth
- Revenue
- 0.0%
- EPS
- +30.0%
- Free Cash Flow
- +19.2%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -69.6%
- ROIC
- -73.2%
Balance Sheet
- Debt/Equity
- 0.16
- Current Ratio
- 12.00
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.